Comparative Pharmacology
Head-to-head clinical analysis: ALKERGOT versus ALMOTRIPTAN MALATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALKERGOT versus ALMOTRIPTAN MALATE.
ALKERGOT vs ALMOTRIPTAN MALATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergotamine tartrate acts as a partial agonist at serotonin (5-HT) receptors, particularly 5-HT1B/1D, and also blocks alpha-adrenergic receptors. It causes vasoconstriction of intracranial blood vessels and reduces extravasation of plasma proteins, thereby alleviating migraine pain. Caffeine enhances ergotamine absorption and may provide additional vasoconstrictive effects.
Selective serotonin 5-HT1B/1D receptor agonist; cranial vasoconstriction and inhibition of trigeminal nerve transmission.
Oral: Ergotamine 1mg/caffeine 100mg combination: 2 tablets at onset of migraine, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack, maximum 10 tablets per week.
12.5 mg orally at onset of migraine; may repeat after 2 hours if headache recurs. Maximum 25 mg/day.
None Documented
None Documented
Terminal elimination half-life is 2–4 hours. Clinical context: Short half-life supports use for acute migraine attacks; frequent dosing may be needed for prolonged symptoms.
Terminal elimination half-life: 3-4 hours. In patients with hepatic impairment, half-life may be prolonged (up to 6-7 hours), necessitating dose adjustment.
Primarily hepatic metabolism followed by biliary and fecal excretion (approx. 90%). Less than 2% is excreted unchanged in urine. Renal elimination of metabolites accounts for about 10%.
Approximately 70% renal excretion (40% unchanged, 30% as metabolites), 30% fecal/biliary elimination.
Category C
Category C
Antimigraine Agent
Antimigraine Agent